The British order with the French-Austrian company has been increased. Negotiations are also underway with the EU. The vaccine is still to be licensed there in 2021.
The UK has increased its order for the planned Corona vaccine from the French-Austrian company Valneva from 60 to 100 million doses.
The 40 million doses are to be delivered next year. There are options for another 90 million doses between 2023 and 2025. Valneva had started production of the active ingredient “VLA2001” at its headquarters in Scotland the previous week.
In addition, the company, which maintains a large research site in Vienna, started the first clinical tests of its vaccine based on inactivated SARS-CoV-2 viruses in humans. The 150 volunteers for the phase I/II trial have been fully recruited and initial results are expected by this April, it said. The UK-based study is being managed from Vienna.
“We are very pleased to be able to extend our supply commitments to the UK. Assuming success, we believe that our vaccine, which has started commercial production at our site in Scotland, can make an important contribution to the UK’s vaccination strategy later this year as well as in 2022,” Valneva Austria chief executive Thomas Lingelbach was quoted as saying in the release. Valneva said it is in “advanced discussions” with the EU Commission about supplying up to 60 million doses. Approval in the EU could take place in the second half of 2021, according to the company’s plan.
Later approval accepted
Among the more than 150 vaccine projects worldwide, this is the only project in the EU and the USA in which the virus is administered as a whole in an inactivated state. The fact that the classical approach will not be among the first approvals was “deliberately chosen”, said Valneva Austria CEO Thomas Lingelbach.
With inactivated vaccines, the body is confronted with viruses that have been rendered harmless. As a result, the body’s own defence system deals with the pathogen and develops the necessary protective immune response. This approach has been tried and tested for many decades.
Since the vaccine is expected to have a long shelf life and standard cold chain storage at temperatures between two and eight degrees Celsius is sufficient, it is suitable for longer-term programmes.
Source: Die Presse